One-year event free survival reported at osteosarcoma conference
OS Therapies has shared positive clinical trial data updates from its Phase IIb clinical trial of immunotherapy candidate OST-HER2 in fully resected, lung metastatic osteosarcoma.
The data were presented by Principal Investigator Dr Damon Reed at the MIB Factor Osteosarcoma Conference held in Salt Lake City, Utah on 28 June.
The results revealed that 35% (14 out of 40) of OST-HER2-treated patients achieved 1-year event free survival (EFS) compared with 20% of patients from peer-reviewed publication selected by Children’s Oncology Group (COG).
A total of 13 out of 40 patients were reported to have experienced severe adverse events (SAEs) during the trial, of which seven patients’ adverse events were treatment-associated adverse events (TSAEs). None of the patients for whom TSAEs were reported discontinued the study.
“The updated OST-HER2 data presented at MIB Factor showed EFS data statistically significantly favouring OST-HER2 treated patients when compared with the leading peer-reviewed publications on historical event free survival outcomes in this subset of the pulmonary metastatic osteosarcoma patient population,” said Dr Robert Petit, Chief Medical & Scientific Officer of OS Therapies. “The favourable safety profile of OST-HER2 compared with standard of care is also an important quality of life factor when assessing potential new treatment options for this difficult to treat patient population.”
OST-HER2 is an immunotherapy for osteosarcoma that uses a HER2-bioengineered form of the bacterium Listeria monocytogenes to trigger a strong immune response against HER2-expressing cancer cells.
Regulatory progress for OST-HER2
Based on guidance from the US Food and Drug Administration (FDA), the company has agreed to provide updated superiority peer-reviewed historical external control data, matched external control data and/or real-world external control data.
This data, individually or collectively at FDA’s discretion, may be sufficient for FDA to support a marketing authorisation in a setting where randomisation may not be feasible due to the rareness of the disease.
The company holds US FDA Orphan Disease Designation (ODD), Fast Track and Rare Pediatric Disease Designation (RPDD) for the prevention or delay of recurrence in fully resected, lung metastatic osteosarcoma.
“The feedback received from FDA regarding the use of external control comparators in settings where placebo-controlled randomisation trials are not feasible increases the avenues available for OST-HER to gain Accelerated Approval,” said Paul Romness, Chairman & CEO of OS Therapies. “Recent interactions we have had with FDA are consistent with public statements from FDA leadership prioritising the safety profile of potential new products under consideration for Accelerated Approval that are intended to treat deadly rare diseases where randomised trials may not be feasible, especially in paediatric cancer where no alternative treatment options are approved.”
In addition, the UK Medicines and Healthcare products Regulatory Agency (MHRA) has agreed to support the Company in utilising its Clinical Practice Research Datalink (CRPD) to assist the Company in developing data necessary to support potential worldwide marketing authorisations – including in the UK, US and EU – for OST-HER2.
Diana Turner, Senior Digital Content Editor, DDW
